Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Flovent HFA pressurized metered dose inhaler · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Investigational Test Product | EXPERIMENTAL | Fluticasone propionate pressurized metered dose inhaler, 110 mcg per actuation |
| Reference Listed Drug | ACTIVE_COMPARATOR | Flovent HFA pressurized metered dose inhaler, 110 mcg per actuation |
| Placebo | PLACEBO_COMPARATOR | Placebo pressurized metered dose inhaler, no active content |
| Name | Type | Description |
|---|---|---|
| Fluticasone propionate pressurized metered dose inhaler | DRUG | 110 mcg per actuation |
| Flovent HFA pressurized metered dose inhaler | DRUG | 110 mcg per actuation |
| Placebo pressurized metered dose inhaler | DRUG | no active content |
Inclusion Criteria: 1. Adult ≥18 and ≤75 years of age male or female subjects of non-child bearing potential or of child bearing potential committing to consistent and correct use of an acceptable method of birth control. 2. Body mass index (BMI) ≥18 and ≤45. 3. Diagnosis of asthma, as defined by t...
Flovent HFA pressurized metered dose inhaler is used for the treatment of asthma. It is a small molecule respiratory medication administered via a pressurized metered dose inhaler. The drug is being developed by Teva Pharmaceutical Industries Limited and is currently in Phase 3 clinical development for this indication.
Flovent HFA pressurized metered dose inhaler contains fluticasone propionate, a corticosteroid that works by reducing inflammation in the airways. It is delivered as a pressurized metered dose inhaler at a strength of 110 mcg. The drug is being studied for its therapeutic equivalence to Flovent HFA 110 mcg in patients with asthma.
Flovent HFA pressurized metered dose inhaler is being developed by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker TEVA. The drug is currently in Phase 3 clinical development for the treatment of asthma, with one completed clinical trial involving 1,902 participants.
Flovent HFA pressurized metered dose inhaler is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for the treatment of asthma, and one Phase 3 clinical trial has been completed to evaluate its therapeutic equivalence to Flovent HFA 110 mcg.
Flovent HFA pressurized metered dose inhaler has one completed Phase 3 clinical trial registered under NCT03879837. The trial, titled "Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg," enrolled 1,902 participants with asthma in the United States. The study was randomized, double-blind, and placebo-controlled.
Flovent HFA pressurized metered dose inhaler is being studied as a therapeutic equivalent to Flovent HFA 110 mcg. The clinical trial NCT03879837 was designed to evaluate whether the fluticasone propionate pressurized metered dose inhaler at 110 mcg is equivalent to the reference product Flovent HFA 110 mcg in patients with asthma.